AstraZeneca (LSE:AZN) received US FDA approval for CALQUENCE as an all oral, fixed duration therapy for chronic lymphocytic ...

The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and ...

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects ...

AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...

AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leu ...

Astrazeneca boss Pascal Soriot was handed his largest ever pay package last year - taking his total earnings at the pharma ...

The drug maker’s annual report showed his total pay lifted 6.4% last year after he was awarded nearly £16 million in bonuses ...

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

Feb 24 (Reuters) - AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) ...

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s AI-native platform in an effort to speed up clinical development.

February 2026 AstraZeneca prices a $2bn bond offering AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced a three tranche global bond offering ...

Investing.com -- AstraZeneca PLC (ST:AZN) announced Friday that the US Food and Drug Administration has approved Calquence in combination with venetoclax as the first all-oral, fixed-duration regimen ...